AstraZeneca invests $2 billion in cancer drug developer Summit Therapeutics
Summit Therapeutics Issuer · AstraZeneca Investor
Intelligence
The deal
- Type
- Funding
- Amount
- $2B
- Structure
- Equity investment alongside an alliance to test ivonescimab with AstraZeneca drugs; no ownership rights handed over
- Status
- Announced
- Round
- Equity investment with alliance
- Valuation
- Not recorded
- Region
- United States
- Date
- 29 September 2026
As of this development: a later development may record new terms.
Lifecycle
- Announced
- Closed
The parties
Summit Therapeutics Issuer
AstraZeneca Investor
Activity